DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for amelogenesis imperfecta type 1G — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAmelogenesis imperfecta type 1G maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for amelogenesis imperfecta type 1g is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein kinase cAMP-dependent type I regulatory subunit alpha (PRKAR1A) — PRKAR1A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pcgdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5KJZ · 1.347 Å · ligand CYCLIC GUANOSINE MONOPHOSPHATE (PCG). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
INDIGO (University of Illinois at Chicago) · 2023 · 0 citations · open access
sj-pptx-1-jdr-10.1177_00220345231203694 – Supplemental material for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes
AbstractSupplemental material, sj-pptx-1-jdr-10.1177_00220345231203694 for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes by U. Hany, C.M. Watson, L. Liu, G. Nikolopoulos, C.E.L. Smith, J.A. Poulter, C.J. Brown, A. Patel, H.D. Rodd, R. Balmer, A. Harfoush, M. Al-Jawad, C.F. Inglehearn and A.J. Mighell in Journal of Dental Research
INDIGO (University of Illinois at Chicago) · 2023 · 0 citations · open access
sj-docx-1-jdr-10.1177_00220345231203694 – Supplemental material for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes
AbstractSupplemental material, sj-docx-1-jdr-10.1177_00220345231203694 for Novel Ameloblastin Variants, Contrasting Amelogenesis Imperfecta Phenotypes by U. Hany, C.M. Watson, L. Liu, G. Nikolopoulos, C.E.L. Smith, J.A. Poulter, C.J. Brown, A. Patel, H.D. Rodd, R. Balmer, A. Harfoush, M. Al-Jawad, C.F. Inglehearn and A.J. Mighell in Journal of Dental Research
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
